Retaspimycin Hydrochloride

็‘žไป–้œ‰็ด 

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRetaspimycin Hydrochloride
Drug Alias Nameretaspimicina็‘žๅธๅŒน้œ‰็ด retaspimycinum็‘ž่žบๆ—‹้œ‰็ด ็‘žไป–้œ‰็ด ็›้…ธ็› +[8]ย 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[11]ย 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8]ย 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInfinity Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInfinity Pharmaceuticals IncAstrazeneca PlcMedimmune Llc
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[11]ย 

Other Information

ATC CodeN/A
Related LinksKEGG